{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/INCY/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T18:18:52.039Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8694,"canonical_name":"INCYTE CORP","cik":"0000879169","uei":null,"lei":null,"duns":null,"ticker":"INCY"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"fda":1,"sec":88,"clinical":31,"open":1},"count":100,"timeline":[{"ts":"20260518","kind":"fda.label","reporter":"Incyte Corporation","title":"ZYNYZ","security_title":"RETIFANLIMAB-DLWR","excerpt":"1 INDICATIONS AND USAGE ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal (SCAC) in combination with carboplatin and paclitaxel for t","accession_number":"109648d0-d30a-42fc-8273-39cb1540a751","route":"INTRAVENOUS","product_type":"HUMAN PRESCRIPTION DRUG","importance":30},{"ts":"2026-07-20","kind":"sec.filing","form_type":"4","title":"4 — Gardner David H — 2026-07-20","url_slug":"/sec/cik-0002085970/4/0002085970-26-000005","accession_number":"0002085970-26-000005","importance":30},{"ts":"2026-07-20","kind":"sec.filing","form_type":"4","title":"4 — Hoffman Richard A. — 2026-07-20","url_slug":"/sec/cik-0002098091/4/0002098091-26-000005","accession_number":"0002098091-26-000005","importance":30},{"ts":"2026-07-16","kind":"sec.form144","reporter":"STEVEN STEIN","title":"Officer","shares":1877,"usd_value":215339,"security_title":"Common","approx_sale_date":"2026-07-16","accession_number":"0001950047-26-007150","importance":40.043067878},{"ts":"2026-07-16","kind":"sec.form144","reporter":"MOHAMED ISSA","title":"Officer","shares":1093,"usd_value":125706,"security_title":"Common","approx_sale_date":"2026-07-16","accession_number":"0001950047-26-007143","importance":40.025141186},{"ts":"2026-07-16","kind":"sec.insider.s","reporter":"Stein Steven H","title":"CMO & Head of Late-Stage Dev.","shares":1877,"price_per_share":114.73,"usd_value":215348,"security_title":"Common Stock","importance":35.21534821},{"ts":"2026-07-16","kind":"sec.insider.s","reporter":"Issa Mohamed Khairie","title":"EVP, Head of U.S. Commercial","shares":1093,"price_per_share":115.01,"usd_value":125706,"security_title":"Common Stock","importance":35.12570593},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"CAGNONI PABLO J","title":"President, Global Head of R&D","shares":13403,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Meury William","title":"Chief Executive Officer","shares":26807,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Stein Steven H","title":"CMO & Head of Late-Stage Dev.","shares":9798,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Tray Thomas","title":"Principal Accounting Officer","shares":2834,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Issa Mohamed Khairie","title":"EVP, Head of U.S. Commercial","shares":7857,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Gardner David H","title":"EVP, Chief Strategy Officer","shares":7395,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Basi Ramitpal K","title":"EVP, Human Resources","shares":4991,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Mayes Patrick A","title":"EVP & Chief Scientific Officer","shares":5916,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-16","kind":"sec.insider.a","reporter":"Hoffman Richard A.","title":"EVP & General Counsel","shares":7395,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-15","kind":"sec.form144","reporter":"STEVEN STEIN","title":"Officer","shares":28237,"usd_value":3192255,"security_title":"Common","approx_sale_date":"2026-07-15","accession_number":"0001950047-26-007087","importance":40.638450994},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"Stein Steven H","title":"CMO & Head of Late-Stage Dev.","shares":28237,"price_per_share":113.05,"usd_value":3192193,"security_title":"Common Stock","importance":38.19219285},{"ts":"2026-07-15","kind":"sec.insider.f","reporter":"CAGNONI PABLO J","title":"President, Global Head of R&D","shares":4950,"price_per_share":115.09,"usd_value":569696,"security_title":"Common Stock","importance":15.5696955},{"ts":"2026-07-15","kind":"sec.insider.f","reporter":"Stein Steven H","title":"CMO & Head of Late-Stage Dev.","shares":3088,"price_per_share":115.09,"usd_value":355398,"security_title":"Common Stock","importance":15.35539792},{"ts":"2026-07-15","kind":"sec.insider.f","reporter":"Mayes Patrick A","title":"EVP & Chief Scientific Officer","shares":1512,"price_per_share":115.09,"usd_value":174016,"security_title":"Common Stock","importance":15.17401608},{"ts":"2026-07-15","kind":"sec.insider.f","reporter":"Issa Mohamed Khairie","title":"EVP, Head of U.S. Commercial","shares":1099,"price_per_share":115.09,"usd_value":126484,"security_title":"Common Stock","importance":15.12648391},{"ts":"2026-07-15","kind":"sec.insider.f","reporter":"Tray Thomas","title":"Principal Accounting Officer","shares":1098,"price_per_share":115.09,"usd_value":126369,"security_title":"Common Stock","importance":15.12636882},{"ts":"2026-07-14","kind":"sec.insider.f","reporter":"Stein Steven H","title":"CMO & Head of Late-Stage Dev.","shares":21830,"price_per_share":114.88,"usd_value":2507830,"security_title":"Common Stock","importance":17.5078304},{"ts":"2026-07-14","kind":"sec.insider.f","reporter":"CAGNONI PABLO J","title":"President, Global Head of R&D","shares":17969,"price_per_share":114.88,"usd_value":2064279,"security_title":"Common Stock","importance":17.06427872},{"ts":"2026-07-14","kind":"sec.insider.f","reporter":"Tray Thomas","title":"Principal Accounting Officer","shares":692,"price_per_share":114.88,"usd_value":79497,"security_title":"Common Stock","importance":15.07949696},{"ts":"2026-07-14","kind":"sec.insider.f","reporter":"Mayes Patrick A","title":"EVP & Chief Scientific Officer","shares":437,"price_per_share":114.88,"usd_value":50203,"security_title":"Common Stock","importance":15.05020256},{"ts":"2026-07-06","kind":"sec.filing","form_type":"8-K","title":"8-K — INCYTE CORP — 2026-07-06","url_slug":"/sec/cik-0000879169/8-k/0000879169-26-000048","accession_number":"0000879169-26-000048","importance":35},{"ts":"2026-07-02","kind":"sec.insider.f","reporter":"Meury William","title":"Chief Executive Officer","shares":4779,"price_per_share":116.86,"usd_value":558474,"security_title":"Common Stock","importance":15.55847394},{"ts":"2026-07-02","kind":"sec.insider.f","reporter":"Stein Steven H","title":"CMO & Head of Late-Stage Dev.","shares":2177,"price_per_share":116.86,"usd_value":254404,"security_title":"Common Stock","importance":15.25440422},{"ts":"2026-07-02","kind":"sec.insider.f","reporter":"Tray Thomas","title":"Principal Accounting Officer","shares":477,"price_per_share":116.86,"usd_value":55742,"security_title":"Common Stock","importance":15.05574222},{"ts":"2026-07-02","kind":"sec.insider.f","reporter":"Mayes Patrick A","title":"EVP & Chief Scientific Officer","shares":350,"price_per_share":116.86,"usd_value":40901,"security_title":"Common Stock","importance":15.040901},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"HARRIGAN EDMUND","title":null,"shares":255,"price_per_share":113.36,"usd_value":28907,"security_title":"Common Stock","importance":15.0289068},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Clancy Paul J","title":null,"shares":252,"price_per_share":113.36,"usd_value":28567,"security_title":"Common Stock","importance":15.02856672},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"BAKER BROS. ADVISORS LP","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"667, L.P.","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Baker Bros. Advisors (GP) LLC","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Baker Brothers Life Sciences LP","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"BAKER FELIX","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"BAKER JULIAN","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"BAKER BROS. ADVISORS LP","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"667, L.P.","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Baker Bros. Advisors (GP) LLC","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Baker Brothers Life Sciences LP","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"BAKER FELIX","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"BAKER JULIAN","title":null,"shares":400,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-22","kind":"sec.filing","form_type":"8-K","title":"8-K — INCYTE CORP — 2026-06-22","url_slug":"/sec/cik-0000879169/8-k/0000879169-26-000046","accession_number":"0000879169-26-000046","importance":35},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — HARRIGAN EDMUND — 2026-06-10","url_slug":"/sec/cik-0001177917/4/0001177917-26-000011","accession_number":"0001177917-26-000011","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"8-K","title":"8-K — INCYTE CORP — 2026-06-08","url_slug":"/sec/cik-0000879169/8-k/0000879169-26-000040","accession_number":"0000879169-26-000040","importance":35},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"BAKER BROS. ADVISORS LP","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"667, L.P.","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"Baker Bros. Advisors (GP) LLC","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"Baker Brothers Life Sciences LP","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"BAKER FELIX","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"BAKER JULIAN","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"BAKER BROS. ADVISORS LP","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"667, L.P.","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"Baker Bros. Advisors (GP) LLC","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"Baker Brothers Life Sciences LP","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"BAKER FELIX","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"BAKER JULIAN","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"HARRIGAN EDMUND","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"BRAWLEY OTIS W","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"BIENAIME JEAN JACQUES","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"FOUSE JACQUALYN A","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"Clancy Paul J","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"High Katherine A","title":null,"shares":1642,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.form144","reporter":"THOMAS R TRAY","title":"Officer","shares":2639,"usd_value":263900,"security_title":"Common","approx_sale_date":"2026-06-04","accession_number":"0001950047-26-005611","importance":40.05278},{"ts":"2026-06-04","kind":"sec.insider.s","reporter":"Tray Thomas","title":"Principal Accounting Officer","shares":2639,"price_per_share":100,"usd_value":263900,"security_title":"Common Stock","importance":35.2639},{"ts":"2026-06-04","kind":"sec.insider.m","reporter":"Tray Thomas","title":"Principal Accounting Officer","shares":2639,"price_per_share":83.83,"usd_value":221227,"security_title":"Common Stock","importance":15.22122737},{"ts":"2026-06-01","kind":"sec.insider.f","reporter":"CAGNONI PABLO J","title":"President, Global Head of R&D","shares":25469,"price_per_share":95.59,"usd_value":2434582,"security_title":"Common Stock","importance":17.43458171},{"ts":"2026-05-19","kind":"sec.form144","reporter":"PAUL J. CLANCY","title":"Director","shares":15000,"usd_value":1424006,"security_title":"Common","approx_sale_date":"2026-05-19","accession_number":"0001950047-26-004755","importance":40.2848011},{"ts":"2026-05-19","kind":"sec.insider.s","reporter":"Clancy Paul J","title":null,"shares":15000,"price_per_share":94.93,"usd_value":1423950,"security_title":"Common Stock","importance":36.42395},{"ts":"2026-05-19","kind":"sec.insider.m","reporter":"Clancy Paul J","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Incyte Corporation","title":"INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders","security_title":"PHASE1,PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04455841","excerpt":"[\"Anemia\",\"Post-essential Thrombocythemia Myelofibrosis\",\"Post-polycythemia Vera Myelofibrosis\"]","importance":45},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Incyte Corporation","title":"A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07588139","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-05-11","kind":"sec.13dg","reporter":"BAKER BROS. ADVISORS LP","shares":31225572,"percent_of_class":15.6,"security_title":"SCHEDULE 13D/A","accession_number":"0001104659-26-058726","excerpt":null,"importance":75},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"Incyte Corporation","title":"Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT01905813","excerpt":"[\"B-cell Malignancies\"]","importance":30},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Incyte Corporation","title":"A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06516952","excerpt":"[\"Prurigo Nodularis\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Incyte Corporation","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07214779","excerpt":"[\"Ovarian Cancer\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Incyte Corporation","title":"Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06855498","excerpt":"[\"Hidradenitis Suppurativa (HS)\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Incyte Corporation","title":"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06585774","excerpt":"[\"Chronic Graft-versus-host-disease\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Incyte Corporation","title":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07023627","excerpt":"[\"Ovarian Cancer\"]","importance":45},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"BAKER BROS. ADVISORS LP","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"667, L.P.","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"Baker Bros. Advisors (GP) LLC","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"Baker Brothers Life Sciences LP","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"BAKER FELIX","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"BAKER JULIAN","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"BAKER BROS. ADVISORS LP","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"667, L.P.","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"Baker Bros. Advisors (GP) LLC","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"Baker Brothers Life Sciences LP","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"BAKER FELIX","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-08","kind":"sec.insider.m","reporter":"BAKER JULIAN","title":null,"shares":15000,"price_per_share":84.53,"usd_value":1267950,"security_title":"Common Stock","importance":16.26795},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Incyte Corporation","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07124078","excerpt":"[\"Chronic Graft-versus-host-disease\"]","importance":45},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Incyte Corporation","title":"A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06909162","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-05-06","kind":"sec.insider.a","reporter":"CAGNONI PABLO J","title":"President, Global Head of R&D","shares":31517,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-06","kind":"sec.insider.a","reporter":"Stein Steven H","title":"CMO & Head of Late-Stage Dev.","shares":44124,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Incyte Corporation","title":"Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05429268","excerpt":"[\"Large B-Cell Lymphoma\",\"Diffuse Large B-Cell Lymphoma\"]","importance":60}]}